000950.SHE C.Q. Pharmaceutical Holding Co Ltd
- Market cap
- CNY 8.84B
- P/E
- 27.2x
- P/B
- 0.73x
- ROE
- 3.6%
- Dividend yield
- 9.88%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000950.SHE undervalued?
Graham number000950.SHE trades 6.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
C.Q. Pharmaceutical Holding Co Ltd fundamental analysis
No fundamental analysis for C.Q. Pharmaceutical Holding Co Ltd yet.
C.Q. Pharmaceutical Holding Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About C.Q. Pharmaceutical Holding Co Ltd
C.Q. Pharmaceutical Holding Co., Ltd. engages in the wholesale and retail of medicines and medical devices. The company is involved in the pharmaceutical commerce, warehousing logistics, pharmaceutical industry, and research and development businesses. It also engages in the hospital pure sales, commercial wholesale, retail chain, warehousing logistics, and supply chain value-added services for drugs, medical devices, Chinese herbal medicines, and health products. The compan…
Full company profileC.Q. Pharmaceutical Holding Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
C.Q. Pharmaceutical Holding Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 20.5B | 21.2B | 25.8B | 33.8B | 45.2B | 62.5B | 67.8B | 78.4B | 80.6B | 82.4B | 80.4B |
| Gross Profit | 1.86B | 2.22B | 2.29B | 3.04B | 4.21B | 5.70B | 5.79B | 6.24B | 5.92B | 5.94B | 5.48B |
| Operating Income | 631M | 1.26B | 847M | 1.12B | 1.37B | 1.56B | 1.44B | 965M | 563M | 1.91B | 1.86B |
| EBITDA | 1.37B | 1.26B | 1.12B | 1.64B | 2.24B | 2.85B | 2.83B | 2.55B | 1.94B | 1.91B | 1.40B |
| Net Income | 956M | 1.11B | 691M | 788M | 884M | 1.01B | 952M | 625M | 283M | 387M | 427M |
| EPS | 2.12 | 0.64 | 0.40 | 0.46 | 0.51 | 0.58 | 0.55 | 0.36 | 0.16 | 0.22 | 0.25 |
| Balance Sheet | |||||||||||
| Total Assets | 5.46B | 15.2B | 20.1B | 25.5B | 42.4B | 49.7B | 57.2B | 63.5B | 66.6B | 66.2B | 67.5B |
| Total Liabilities | 4.42B | 7.95B | 12.0B | 16.6B | 32.0B | 37.9B | 44.5B | 48.0B | 50.2B | 49.7B | 50.8B |
| Shareholders' Equity | 1.04B | 6.72B | 7.32B | 8.07B | 8.84B | 9.82B | 10.7B | 11.2B | 11.3B | 11.5B | 11.8B |
| Cash & Short-term Investments | 261M | 1.92B | 2.55B | 3.36B | 4.69B | 5.68B | 7.43B | 9.15B | 9.39B | 6.68B | 4.51B |
| Total Debt | 2.39B | 879M | 4.15B | 6.72B | 15.3B | 18.2B | 22.1B | 23.1B | 20.9B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 248M | -1.10B | -1.71B | 202M | 632M | 250M | 286M | 509M | -187M | 755M | - |
| Capital Expenditure | 141M | 151M | 304M | 821M | 378M | 490M | 268M | 244M | 251M | 300M | 313M |
| Free Cash Flow | 106M | -1.25B | -2.01B | -619M | 254M | -239M | 17.8M | 264M | -437M | 455M | -4.82B |
| Ratios | |||||||||||
| ROE | 92.1% | 16.5% | 9.4% | 9.8% | 10.0% | 10.2% | 8.9% | 5.6% | 2.5% | 3.4% | 3.6% |
| ROA | 17.5% | 7.3% | 3.4% | 3.1% | 2.1% | 2.0% | 1.7% | 1.0% | 0.4% | 0.6% | 0.6% |
| Net Profit Margin | 4.7% | 5.2% | 2.7% | 2.3% | 2.0% | 1.6% | 1.4% | 0.8% | 0.4% | 0.5% | 0.5% |
| Debt to Equity | 2.30x | 0.13x | 0.57x | 0.83x | 1.73x | 1.85x | 2.08x | 2.05x | 1.84x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
C.Q. Pharmaceutical Holding Co Ltd dividends
- Dividend yield
- 9.88%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 225.9%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 874M | 0.51 | 225.9% |
| 2024 | CNY 1.12B | 0.63 | 395.8% |
| 2023 | CNY 1.30B | 0.75 | 208.0% |
| 2022 | CNY 112M | 0.06 | 11.8% |
| 2021 | CNY 69.1M | 0.04 | 6.9% |
| 2020 | CNY 86.4M | 0.05 | 9.8% |
| 2019 | CNY 275M | 0.16 | 34.9% |
| 2018 | CNY 127M | 0.07 | 18.4% |
| 2017 | CNY 123M | 0.07 | 11.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Apr 16, 2010.
Who owns C.Q. Pharmaceutical Holding Co Ltd
- Insiders 60.73%
- Institutions 4.45%
- Public & others 34.82%
- Shares outstanding 1.71B
- Free float 722M
C.Q. Pharmaceutical Holding Co Ltd company profile
- Company name
- C.Q. Pharmaceutical Holding Co Ltd
- Ticker
- 000950.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 12,237
- Fiscal year end
- December
- Address
- No. 303, Jinshi Avenue, Chongqing, China, 400010
- Phone
- 86 23 6391 0671
- Website
- cqphar.com
About C.Q. Pharmaceutical Holding Co Ltd
C.Q. Pharmaceutical Holding Co., Ltd. engages in the wholesale and retail of medicines and medical devices. The company is involved in the pharmaceutical commerce, warehousing logistics, pharmaceutical industry, and research and development businesses. It also engages in the hospital pure sales, commercial wholesale, retail chain, warehousing logistics, and supply chain value-added services for drugs, medical devices, Chinese herbal medicines, and health products. The company was formerly known as Southwest Branch of China Medicine Company. C.Q. Pharmaceutical Holding Co., Ltd. was founded in 1999 and is based in Chongqing, China.
C.Q. Pharmaceutical Holding Co Ltd management
8- Mr. Wei LiuGM & Director · born 1975
- Mr. Tian Qiu CPAFinancial Director, CFO & Board Secretary · born 1986
- Mr. Lei YangChief Accountant · born 1974
- Mr. Zhang ShunGeneral Counsel · born 1975
- Mr. Shaohong LiExecutive Deputy GM & Director · born 1970
- Mr. Yihai ChenDeputy GM & Non-Independent Director · born 1970
- Ms. Qinghua YangDeputy General Manager · born 1972
- Mr. Wei LiuDeputy General Manager · born 1968